Arcellx, Inc. (ACLX) FY2025 10-K Annual Report
Arcellx, Inc. (ACLX) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Feb 26, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
Arcellx, Inc. FY2025 10-K Analysis
Business Overview
- • Core business: Clinical-stage biotech developing novel D-Domain powered CAR-T immunotherapies for cancer and autoimmune diseases
- • New emphasis: ARC-SparX universal CAR-T platform and expanded non-oncology trials including Phase 1 generalized Myasthenia Gravis (gMG) dosing in 2025
Risk Factors
- • Regulatory risk: Hart-Scott-Rodino Antitrust Act clearance required for Gilead merger, with timing and approval uncertainty risking deal abandonment
- • Macroeconomic risk: Global pandemics and U.S. trade policy changes may disrupt operations and third-party providers critical to business
Arcellx, Inc. FY2025 Key Financial MetricsXBRL
Revenue
$22M
▼ -79.4% YoY
Net Income
-$229M
▼ -113.3% YoY
Operating Margin
-1135.6%
▼ -100816bp YoY
Net Margin
-1027.3%
▼ -92780bp YoY
ROE
-56.9%
▼ -3330bp YoY
Total Assets
$604M
▼ -15.1% YoY
EPS (Diluted)
$-4.07
▼ -103.5% YoY
Operating Cash Flow
-$210M
▼ -151.9% YoY
Source: XBRL data from Arcellx, Inc. FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Arcellx, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.